The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

about

The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

Item

http://www.wikidata.org/entity/Q58799989

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

The Winding Roadmap of Biomark ...... n Metastatic Colorectal Cancer

@en

The Winding Roadmap of Biomark ...... n Metastatic Colorectal Cancer

@nl

type

Item

label

The Winding Roadmap of Biomark ...... n Metastatic Colorectal Cancer

@en

The Winding Roadmap of Biomark ...... n Metastatic Colorectal Cancer

@nl

prefLabel

The Winding Roadmap of Biomark ...... n Metastatic Colorectal Cancer

@en

The Winding Roadmap of Biomark ...... n Metastatic Colorectal Cancer

@nl

P1476

The Winding Roadmap of Biomark ...... n Metastatic Colorectal Cancer

@en

P2093

Carlotta Antoniotti

http://www.w3.org/2001/XMLSchema#string

Elena Ongaro

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

P304

2298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3390/IJMS19082298

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alfredo Falcone

Chiara Cremolini

P577

2018-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30081606

http://www.w3.org/2001/XMLSchema#string

P921

P932

6121538

http://www.w3.org/2001/XMLSchema#string